www.analyticsdrift.com
Image source: Analytics Drift
Insilico Medicine, the Hong Kong-based biotech startup, has begun human trials of its AI-designed drug.
Image source: Insilico
Known as INS018-055, the fully generative AI drug is targeted to treat idiopathic pulmonary fibrosis (IPF), a chronic disease that causes scarring in the lungs.
Image source: Canva
The condition is prevalent in about 100,000 people in the United States and, if left untreated, can lead to death in 2-5 years, according to the National Institutes of Health.
Image source: Canva
“There are very few options for people with this terrible condition, and the prognosis is poor,” said Insilico Medicine’s CEO Alex Zhavoronkov.
Image source: Insilico
Initial studies indicate that INS018_055 has the potential to address some of the limitations of existing therapies.
Image source: Canva
The drug received positive topline data in Phase I in early 2023, with international multi-site Phase I studies demonstrating consistent results.
Image source: Canva
A 12-week trial will include subjects diagnosed with IPF, and the Phase II study will assess the tolerability, safety, preliminary efficacy, and pharmacokinetics of the drug.
Image source: Canva
Insilico’s chief medical officer, Sujata Rao, M.D., stated, “If our Phase IIa study is successful, the drug will then go to Phase IIb with a larger cohort of participants.”
Image source: Insilico
Get the latest updates on AI developments.
Produced by: Suchitra Shenoy Designed by: Prathamesh